Skip to main content

Table 1 Part 1. Patient characteristics and associations with inflammatory response after cardiopulmonary bypass

From: Tranexamic acid attenuates inflammatory response in cardiopulmonary bypass surgery through blockade of fibrinolysis: a case control study followed by a randomized double-blind controlled trial

Variables Inflammatory response (n = 34) No inflammatory response (n = 131) P value
Age, years 61 ± 12 61 ± 13 0.97
Gender    
   Male, number (percentage) 24 (70) 88 (67) 0.70
   Female, number (percentage) 10 (30) 43 (33) 0.70
Body mass index, kg/m2 28.5 ± 5 27.5 ± 4.2 0.20
Parsonnet score 13.6 ± 9.2 12.1 ± 6.8 0.35
Comorbidity    
   Renal disease, number (percentage) 4 (11) 8 (6) 0.26
   Diabetic status, number (percentage) 12 (35) 44 (34) 0.85
   Angiotensin-converting enzyme inhibitors, number (percentage) 10 (29) 45 (34) 0.58
Cardiac intervention    
   Coronary, number (percentage) 19 (56) 81 (62) 0.20
   Valvular, number (percentage) 9 (26) 41 (31) 0.58
   Both, number (percentage) 6 (17) 9 (7) 0.051
   Reintervention, number (percentage) 2 (6) 6 (5) 0.75
Surgical data    
   Total cardiopulmonary bypass time, minutes 101 ± 33 93 ± 33 0.20
   Aortic clamping time, minutes 61.6 ± 27.3 54 ± 22.8 0.11
   Tranexamic acid, number (percentage) 8 (26) 78 (60) <0.01
   No antifibrinolytics, number (percentage) 26 (76) 53 (40) 0.44
   Intensive care unit stay, days 7.8 ± 6.4 3.2 ± 1.7 <0.01
   Hospital stay, days 17.6 ± 20.5 9.1 ± 6.2 <0.01
  1. Values are expressed as mean ± standard deviation.